NCT02803385

Brief Summary

This study aims to compare the efficacy of pain control, the consumption of local anesthetic and opioids, side effects, and patient satisfaction between continuous epidural infusion and patient controlled epidural analgesia after thoraco-abdominal surgeries in cancer patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable pain

Timeline
Completed

Started Jul 2016

Longer than P75 for not_applicable pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 8, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 17, 2016

Completed
14 days until next milestone

Study Start

First participant enrolled

July 1, 2016

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2019

Completed
Last Updated

October 6, 2021

Status Verified

October 1, 2021

Enrollment Period

2.4 years

First QC Date

June 8, 2016

Last Update Submit

October 5, 2021

Conditions

Keywords

Patient Controlled Epidural AnalgesiaContinous Epidural Infusion Analgesia

Outcome Measures

Primary Outcomes (1)

  • To compare the pain scores during rest and movement with continuous epidural infusion (CEI) vs. patient controlled epidural analgesia (PCEA)

    pain scores to be assessed using Numerical Rating scale(1-10)

    72 hours

Secondary Outcomes (2)

  • To compare patient satisfaction between the two groups using Verbal Rating scale

    36 hours and 72 hours

  • To assess the incidence of side effects in both groups including hypotension, motor weakness, pruritus, nausea, vomiting and any other

    72 hours

Study Arms (2)

Continous Epidural Analgesia

ACTIVE COMPARATOR

Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes

Other: Continous Epidural Analgesia

Patient Controlled Epidural Analgesia

ACTIVE COMPARATOR

Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .

Other: Patient Controlled Epidural Analgesia

Interventions

continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.

Also known as: continous epidural infusion of local anesthetic with opioid
Continous Epidural Analgesia

patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.

Also known as: patient controlled boluses of local anesthetic with opioid
Patient Controlled Epidural Analgesia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All adult patients, American Society of Anaesthesia class I-II, posted for thoraco-abdominal surgeries and planned for epidural catheter insertion for perioperative pain management, will be included. The surgeries will include gastrectomy, radical \& revision cholecystectomy, whipples procedure, pancreatectomy, lobectomy, metastectomy, pneumonectomy will be included.

You may not qualify if:

  • Patients with contraindication to epidural catheter placement or use of opioids or local anesthetic
  • Patients with contraindication to use of rescue analgesia like paracetamol and diclofenac both in postoperative period
  • Multiple incision not covered with epidural like TTE, THE
  • Patients with failed epidural insertion
  • Patients with epidural band not covering the incision sites completely
  • Patient with hemodynamic instability leading to inability to use epidural within the first 4-6 hours.
  • Patient shifted on ventilator or needing ventilator support the within first 6-12 hours.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tata Memorial Hospital

Mumbai, Maharashtra, 400012, India

Location

Related Publications (3)

  • Liu SS, Allen HW, Olsson GL. Patient-controlled epidural analgesia with bupivacaine and fentanyl on hospital wards: prospective experience with 1,030 surgical patients. Anesthesiology. 1998 Mar;88(3):688-95. doi: 10.1097/00000542-199803000-00020.

  • Komatsu H, Matsumoto S, Mitsuhata H, Abe K, Toriyabe S. Comparison of patient-controlled epidural analgesia with and without background infusion after gastrectomy. Anesth Analg. 1998 Oct;87(4):907-10. doi: 10.1097/00000539-199810000-00030.

  • Standl T, Burmeister MA, Ohnesorge H, Wilhelm S, Striepke M, Gottschalk A, Horn EP, Schulte Am Esch J. Patient-controlled epidural analgesia reduces analgesic requirements compared to continuous epidural infusion after major abdominal surgery. Can J Anaesth. 2003 Mar;50(3):258-64. doi: 10.1007/BF03017795.

MeSH Terms

Conditions

Pain

Interventions

Analgesics, Opioid

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

NarcoticsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesAnalgesicsSensory System AgentsPeripheral Nervous System AgentsCentral Nervous System AgentsTherapeutic Uses

Study Officials

  • Parmanand Jain, MD, MNAMS

    Professor

    PRINCIPAL INVESTIGATOR
  • Sumitra Bakshi, MD

    Professor

    STUDY CHAIR
  • Ankita Lapalikar, MBBS

    Student

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 8, 2016

First Posted

June 17, 2016

Study Start

July 1, 2016

Primary Completion

December 1, 2018

Study Completion

January 1, 2019

Last Updated

October 6, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations